These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 11363485)

  • 21. Liposomal anthracycline chemotherapy and the risk of second malignancies in patients with Kaposi's sarcoma (KS).
    Bendle M; Pealing J; Papanastasopoulos P; Bower M
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):611-5. PubMed ID: 25055936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated mucocutaneous Kaposi's sarcoma.
    Girard PM; Bouchaud O; Goetschel A; Mukwaya G; Eestermans G; Ross M; Rozenbaum W; Saimot AG
    AIDS; 1996 Jun; 10(7):753-7. PubMed ID: 8805866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of liposomal anthracyclines in Kaposi's sarcoma.
    Krown SE; Northfelt DW; Osoba D; Stewart JS
    Semin Oncol; 2004 Dec; 31(6 Suppl 13):36-52. PubMed ID: 15717737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma.
    Bennett CL; Golub RM; Stinson TJ; Aboulafia DM; von Roenn J; Bogner J; Goebel FD; Stewart S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Aug; 18(5):460-5. PubMed ID: 9715842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacology of liposomal daunorubicin and its use in Kaposi's sarcoma.
    Chew T; Jacobs M
    Oncology (Williston Park); 1996 Jun; 10(6 Suppl):28-33; discussion 37-8. PubMed ID: 16871707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liposomal anthracyclines for breast cancer.
    Sparano JA; Winer EP
    Semin Oncol; 2001 Aug; 28(4 Suppl 12):32-40. PubMed ID: 11552228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New treatment for KS offers options for therapy.
    AIDS Alert; 1996 Feb; 11(2):21-2. PubMed ID: 11363236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liposomal daunorubicin marketed for HIV-related Kaposi's sarcoma.
    Am J Health Syst Pharm; 1996 Jul; 53(13):1500, 1505. PubMed ID: 8809269
    [No Abstract]   [Full Text] [Related]  

  • 29. Liposomal encapsulated anthracyclines: new therapeutic horizons.
    Muggia FM
    Curr Oncol Rep; 2001 Mar; 3(2):156-62. PubMed ID: 11177748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin.
    Gill PS; Espina BM; Muggia F; Cabriales S; Tulpule A; Esplin JA; Liebman HA; Forssen E; Ross ME; Levine AM
    J Clin Oncol; 1995 Apr; 13(4):996-1003. PubMed ID: 7707129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma.
    Hjortsberg C; Persson U; Lidbrink E; Bennett C
    Acta Oncol; 1999; 38(8):1063-7. PubMed ID: 10665764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma.
    Amantea MA; Forrest A; Northfelt DW; Mamelok R
    Clin Pharmacol Ther; 1997 Mar; 61(3):301-11. PubMed ID: 9084455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized cross-over comparison of liposomal daunorubicin versus observation for early Kaposi's sarcoma.
    Uthayakumar S; Bower M; Money-Kyrle J; Muyshondt C; Youle M; Hannon F; Phillips R; Gazzard BG; Boag F
    AIDS; 1996 May; 10(5):515-9. PubMed ID: 8724043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early approval for two lipid-based drugs.
    Baker R
    BETA; 1995 Dec; ():4. PubMed ID: 11363009
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disseminated classic Kaposi's sarcoma. Two cases with excellent response to pegylated liposomal doxorubicin.
    Castiñeiras I; Almagro M; Rodríguez-Lozano J; Fernández-Jorge B; Paradela S; Pozo JD; Fonseca E
    J Dermatolog Treat; 2006; 17(6):377-80. PubMed ID: 17853313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. KS: a new drug and, maybe, a new bug.
    Gilden D
    GMHC Treat Issues; 1995 Jan; 9(1):11-12. PubMed ID: 11367378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia.
    Russo D; Piccaluga PP; Michieli M; Michelutti T; Visani G; Gugliotta L; Bonini A; Pierri I; Gobbi M; Tiribelli M; Fanin R; Piccolrovazzi S; Baccarani M
    Ann Hematol; 2002 Aug; 81(8):462-6. PubMed ID: 12224004
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi's sarcoma.
    Tulpule A; Yung RC; Wernz J; Espina BM; Myers A; Scadden DT; Cabriales S; Ilaw M; Boswell W; Gill PS
    J Clin Oncol; 1998 Oct; 16(10):3369-74. PubMed ID: 9779714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liposomal drug targeting in the treatment of Kaposi's sarcoma.
    Wernz JC
    AIDS Patient Care STDS; 1996 Dec; 10(6):362-7. PubMed ID: 11361553
    [No Abstract]   [Full Text] [Related]  

  • 40. Liposomal daunorubicin as treatment for Kaposi's sarcoma.
    Petre CE; Dittmer DP
    Int J Nanomedicine; 2007; 2(3):277-88. PubMed ID: 18019828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.